Latest Conference Articles

December 7th 2018, 10:39pm

San Antonio Breast Cancer Symposium

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.

December 7th 2018, 10:26pm

San Antonio Breast Cancer Symposium

The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.

December 7th 2018, 10:13pm

San Antonio Breast Cancer Symposium

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

December 7th 2018, 9:25pm

San Antonio Breast Cancer Symposium

Combining the BCL-2 inhibitor venetoclax with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor–positive and BCL-2–positive metastatic breast cancer.

December 7th 2018, 7:49pm

San Antonio Breast Cancer Symposium

Laura Spring, MD, medical oncologist at Massachusetts General Hospital Cancer Center and instructor in medicine at Harvard Medical School, discusses the association between pathologic complete response (pCR) and neoadjuvant chemotherapy in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

December 7th 2018, 7:47pm

San Antonio Breast Cancer Symposium

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the randomized trial evaluating the effectiveness of oxybutynin chloride in the management of hot flashes in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

December 7th 2018, 3:06am

San Antonio Breast Cancer Symposium

Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with PIK3CA-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.

December 7th 2018, 2:21am

San Antonio Breast Cancer Symposium

U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.

December 7th 2018, 1:40am

San Antonio Breast Cancer Symposium

Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.

December 7th 2018, 12:44am

San Antonio Breast Cancer Symposium

Accelerated partial breast irradiation following lumpectomy was marginally not found to be equivalent to whole breast irradiation to control ipsilateral breast tumor recurrence.

December 7th 2018, 12:35am

San Antonio Breast Cancer Symposium

A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.

December 7th 2018, 12:17am

San Antonio Breast Cancer Symposium

The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.

December 6th 2018, 11:40pm

San Antonio Breast Cancer Symposium

The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

December 6th 2018, 7:39pm

San Antonio Breast Cancer Symposium

Francois-Clement Bidard, MD, PhD, professor, medical oncologist, Institut Curie, discusses the clinical utility of circulating tumor cell count (CTC) in breast cancer at the 2018 San Antonio Breast Cancer Symposium.

December 6th 2018, 7:36pm

San Antonio Breast Cancer Symposium

Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, compares the use of partial breast irradiation (PBI) with that of whole breast irradiation (WBI) in women with early-stage breast cancer at the 2018 San Antonio Breast Cancer Symposium.

December 6th 2018, 6:53pm

San Antonio Breast Cancer Symposium

Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.

December 6th 2018, 3:32am

San Antonio Breast Cancer Symposium

Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.

December 6th 2018, 1:51am

San Antonio Breast Cancer Symposium

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.

December 6th 2018, 1:50am

San Antonio Breast Cancer Symposium

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the association between cardiovascular medication and cardiovascular events following a diagnosis of early-stage breast cancer during the 2018 San Antonio Breast Cancer Symposium.

December 6th 2018, 12:51am

San Antonio Breast Cancer Symposium

Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.